FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Aldeyra Therapeutics Inc. Rises Following Positive Phase 3 Clinical Trial Results”
Aldeyra Therapeutics Inc (NASDAQ: ALDX) surged over 15% in premarket trading after the company announced positive top-line results from the Phase 3 INVIGORATE Clinical Trial.
The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints, and there were no observed safety or tolerability concerns in the INVIGORATE Trial of Reproxalap in Allergic Conjunctivitis.
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis.
For more information, please visit: Aldeyra Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.